What is Anktiva?
Anktiva (nogapendekin alfa inbakicept-pmln) is a novel IL-15 superagonist immunotherapy used in the treatment of bladder cancer.
Yanuki
ARTICLE DETAIL
ImmunityBio's Anktiva: Asian Expansion and NCCN Guideline Inclusion | William Shatner's Secrets to Staying Active and Full of Life at 95 | Former South Carolina QB Stephen Garcia Diagnosed with Stage 4 Colorectal Cancer | Norovirus Outbreak on Caribbean Princess Cruise Ship | Jordan Peterson's Health Concerns and Akathisia Awareness | Fiji Grapples with Soaring HIV Cases: An Alarming Outbreak | Newborns Bleeding to Death in US: The Vitamin K Debate | Dave Coulier Reveals 45-Pound Weight Loss from Cancer Treatment | Biohacking Vaginal Health: Trends and Insights | ImmunityBio's Anktiva: Asian Expansion and NCCN Guideline Inclusion | William Shatner's Secrets to Staying Active and Full of Life at 95 | Former South Carolina QB Stephen Garcia Diagnosed with Stage 4 Colorectal Cancer | Norovirus Outbreak on Caribbean Princess Cruise Ship | Jordan Peterson's Health Concerns and Akathisia Awareness | Fiji Grapples with Soaring HIV Cases: An Alarming Outbreak | Newborns Bleeding to Death in US: The Vitamin K Debate | Dave Coulier Reveals 45-Pound Weight Loss from Cancer Treatment | Biohacking Vaginal Health: Trends and Insights
Health / Cancer Treatment
ImmunityBio's Anktiva: Asian Expansion and NCCN Guideline Inclusion
ImmunityBio's Anktiva (nogapendekin alfa inbakicept-pmln) is making significant strides in bladder cancer treatment. Recently, it secured approval in Macau, marking its expansion into Asia, and was added to the National Comprehensive Cancer...
Key Insights
- Anktiva Receives Macau Approval: ImmunityBio's Anktiva has been approved for marketing and sale in Macau, its first entry into the Asian market. This is an important step in the company's broader international expansion strategy.
- NCCN Guideline Inclusion: The NCCN has updated its guidelines to include Anktiva plus Bacillus Calmette-Guérin (BCG) as a Category 2A recommendation for patients with BCG-unresponsive papillary-only non-muscle invasive bladder cancer (NMIBC).
- Clinical Trial Success: The guideline update is supported by data from the QUILT-3.032 trial, which showed a 2% disease-free survival rate at 12 months and durable responses up to 36 months.
- Bladder Preservation: The QUILT-3.032 trial also demonstrated an 81.8% cystectomy-free survival rate at 36 months, indicating that Anktiva + BCG can help patients avoid bladder removal.
- Why This Matters: These developments provide new hope for patients with bladder cancer, offering a bladder-sparing immunotherapy option and expanding access to treatment in Asia.
In-Depth Analysis
ImmunityBio's Anktiva is a novel IL-15 superagonist immunotherapy that works by activating the immune system's natural killer (NK) cells and memory T cells. When used in combination with BCG, it amplifies the immune response against bladder cancer cells.
**Macau Approval** The approval in Macau is a significant milestone for ImmunityBio, representing its first foray into the Asian market. The company is also engaging with health authorities across the Asia-Pacific region to pursue further regulatory authorizations.
**NCCN Guideline Update** The NCCN's decision to include Anktiva in its guidelines for papillary-only NMIBC is based on compelling clinical evidence from the QUILT-3.032 trial. This update expands the use of Anktiva beyond its initial FDA approval for carcinoma in situ (CIS), offering a new treatment option for patients who have exhausted standard BCG therapy. The recommendation is classified as Category 2A, indicating uniform consensus by NCCN experts despite reliance on phase 2/3 trial data rather than phase 3 alone.
**QUILT-3.032 Trial Results** The QUILT-3.032 trial enrolled patients with high-grade papillary-only BCG-unresponsive NMIBC. The results showed:
- 2% of patients remained disease-free at 12 months.
- Durable responses with 52.1% DFS at 24 months and 38.2% DFS at 36 months.
- High progression-free survival (PFS) and disease-specific survival (DSS) rates at 36 months (83.1% and 96.0%, respectively).
- 8% cystectomy-free survival rate at 36 months.
These results, published in the Journal of Urology, demonstrate that Anktiva + BCG can provide prolonged remission and reduce the risk of bladder cancer progression and mortality.
FAQ
What is BCG?
BCG (Bacillus Calmette-Guérin) is a bacterium used to stimulate the immune system to fight bladder cancer cells.
What is NMIBC?
NMIBC stands for non-muscle invasive bladder cancer, a type of bladder cancer that has not spread to the muscle layer of the bladder wall.
What is the NCCN?
The National Comprehensive Cancer Network (NCCN) is a non-profit alliance of leading cancer centers dedicated to improving the quality and effectiveness of cancer care.
Takeaways
- Anktiva is now approved in Macau, expanding its availability to patients in Asia.
- The NCCN has included Anktiva in its guidelines for papillary-only NMIBC, providing a new treatment option for patients who have failed BCG therapy.
- Clinical trial data support the use of Anktiva + BCG for durable remission and bladder preservation.
- Patients with BCG-unresponsive papillary-only NMIBC now have a bladder-sparing immunotherapy alternative to consider.
Discussion
What are your thoughts on the potential of Anktiva in bladder cancer treatment? Share this article with others who need to stay ahead of this trend!
Sources
Disclaimer
This article was compiled by Yanuki using publicly available data and trending information. The content may summarize or reference third-party sources that have not been independently verified. While we aim to provide timely and accurate insights, the information presented may be incomplete or outdated.
All content is provided for general informational purposes only and does not constitute financial, legal, or professional advice. Yanuki makes no representations or warranties regarding the reliability or completeness of the information.
This article may include links to external sources for further context. These links are provided for convenience only and do not imply endorsement.
Always do your own research (DYOR) before making any decisions based on the information presented.